Tahara H, Naito H, Kise K, Wakabayashi T, Kamoi K, Okihara K, Yanagisawa A, Nakai Y, Nonomura N, Morii E, Miki T, Takakura N
1] Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan [2] Department of Urology, Kyoto Prefectural University of Medicine, Kamigyou-ku, Kyoto, Japan.
Department of Signal Transduction, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka, Japan.
Prostate Cancer Prostatic Dis. 2015 Mar;18(1):56-62. doi: 10.1038/pcan.2014.46. Epub 2014 Nov 18.
Partner of SLD5 1 (PSF1) is an evolutionarily conserved DNA replication factor. Previous studies have suggested that transcriptional activity of the PSF1 gene correlated with malignancy of cancer cells. The objective of the current study was to evaluate the relationship between PSF1 expression and the clinical features of prostate cancer.
We determined the expression of PSF1 in 120 needle biopsy samples of prostate cancer by immunohistochemistry. We divided patients into PSF1-positive or -negative groups and analyzed the relationships between the expression of PSF1, the Gleason score, PSA level, TNM classification and prognosis.
Our results showed that the PSF1 expression correlated significantly with PSA values at diagnosis (P=0.0028), with tumor grade (P<0.0001), and with clinical stage (P=0.0005). Moreover, the PSF1 expression correlated significantly with overall survival (hazard ratio (HR) 5.5; 95% confidence interval (CI) 2.17-15.8; P=0.003) and progression-free survival in 99 consecutive patients with prostate cancer. Noteworthy, the prognosis of PSF1-positive cases was also worse in patients with a Gleason score of 8-10 (HR 3.7; 95% CI 1.28-13.43; P=0.0143). Limitations include that this study had a retrospective design, that patients in the study were heterogeneous and included those with early and advanced cancer, and that small tumor fragments may not be representative of the entire carcinoma.
PSF1 is expressed in high-grade prostate cancer and may be a useful biomarker to identify patients with a poor prognosis at the time of diagnosis.
SLD5 1的伙伴蛋白（PSF1）是一种进化上保守的DNA复制因子。先前的研究表明，PSF1基因的转录活性与癌细胞的恶性程度相关。本研究的目的是评估PSF1表达与前列腺癌临床特征之间的关系。
我们通过免疫组织化学测定了120例前列腺癌穿刺活检样本中PSF1的表达。我们将患者分为PSF1阳性或阴性组，并分析了PSF1表达、Gleason评分、PSA水平、TNM分期与预后之间的关系。
我们的结果显示，PSF1表达与诊断时的PSA值显著相关（P = 0.0028），与肿瘤分级显著相关（P < 0.0001），与临床分期显著相关（P = 0.0005）。此外，在99例连续的前列腺癌患者中，PSF1表达与总生存期（风险比（HR）5.5；95%置信区间（CI）2.17 - 15.8；P = 0.003）和无进展生存期显著相关。值得注意的是，在Gleason评分为8 - 10的患者中，PSF1阳性病例的预后也较差（HR 3.7；95% CI 1.28 - 13.43；P = 0.0143）。局限性包括本研究为回顾性设计，研究中的患者具有异质性，包括早期和晚期癌症患者，以及小肿瘤碎片可能不代表整个癌组织。
PSF1在高级别前列腺癌中表达，可能成为诊断时识别预后不良患者的有用生物标志物。
